UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


FORM 10-Q

 


 

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 29, 2005.

FOR THE QUARTERLY PERIOD ENDED JANUARY 28, 2006.

 

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File No. 0-20572

 


PATTERSON COMPANIES, INC.

(Exact name of registrant as specified in its charter)

 


 

Minnesota 41-0886515
(State of incorporation) (I.R.S. Employer Identification No.)

1031 Mendota Heights Road, St. Paul, Minnesota 55120

(Address of principal executive offices, including zip code)

(651) 686-1600

(Registrant’s telephone number, including area code)

 


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    x  Yes    ¨  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, (as definedor a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in ruleRule 12b-2 of the Exchange Act.)Act

Large Accelerated Filer  x     YesAccelerated Filer  ¨    NoNon-Accelerated Filer  

¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    ¨  Yes    x  No

Patterson Companies, Inc. had outstanding 138,278,316138,642,997 shares of common stock as of DecemberMarch 6, 2005.2006.

 



PATTERSON COMPANIES, INC.

INDEX

 

   

Page


PART I -FINANCIAL INFORMATION  
Item 1 - Financial Statements (Unaudited)3-12
 

Item 1 -

Financial Statements (Unaudited)3-11
 Condensed Consolidated Balance Sheets as of October 29, 2005January 28, 2006 and April 30, 2005  3
  Condensed Consolidated Statements of Income for the Three And Sixand Nine Months Ended OctoberJanuary 28, 2006 and January 29, 2005 and October 30, 2004  4
  Condensed Consolidated Statements of Cash Flows for the SixNine Months Ended OctoberJanuary 28, 2006 and January 29, 2005 and October 30, 2004  5
  Notes to Condensed Consolidated Financial Statements  6-116-12

Item 2 -

 Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations  12-17

Item 3 -

 Item 3 - Quantitative and Qualitative Disclosures About Market Risk  1817

Item 4 -

 Item 4 - Controls and Procedures  18

PART II -OTHER INFORMATION

  

Item 1 –

 Item 1 – Legal Proceedings  19

Item 2 -

 Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds  19

Item 4 –

 Submission of Matters to a Vote of Security HoldersItem 6 - Exhibits  19-2019

Item 6 -

 ExhibitsSignatures  20
 

SignaturesExhibit Index

  21

Exhibit Index

22

Safe Harbor Statement Under The Private Securities Litigation Reform Act Of 1995:

This Form 10-Q for the period ended October 29, 2005,January 28, 2006, contains certain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, which may be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “anticipate”, “estimate”, “believe”, “goal”, or “continue”, or comparable terminology that involves risks and uncertainties that are qualified in their entirety by cautionary language set forth herein under the caption “Factors That May Affect Future Operating Results,” in the Company’s 2005 Annual Report on Form 10-K filed July 14, 2005, and other documents previously filed with the Securities and Exchange Commission.

PART I - FINANCIAL INFORMATION

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in thousands)

 

   October 29,
2005


  April 30,
2005


 
   (Unaudited)    

ASSETS

         

Current assets:

         

Cash and cash equivalents

  $148,047  $232,549 

Short-term investments

   4,013   13,382 

Receivables, net

   341,258   317,168 

Inventory

   237,011   206,405 

Prepaid expenses and other current assets

   30,088   30,533 
   


 


Total current assets

   760,417   800,037 

Property and equipment, net

   119,820   97,178 

Long-term receivables, net

   34,394   33,573 

Goodwill

   649,184   632,549 

Identifiable intangibles, net

   111,357   113,530 

Distribution agreement

   100,000   —   

Other

   7,940   8,434 
   


 


Total assets

  $1,783,112  $1,685,301 
   


 


LIABILITIES AND STOCKHOLDERS’ EQUITY

         

Current liabilities:

         

Accounts payable

  $173,096  $160,954 

Accrued payroll expense

   47,157   43,132 

Other accrued expenses

   83,438   77,317 

Income taxes payable

   3,734   20,858 

Current maturities of long-term debt

   21,527   20,027 
   


 


Total current liabilities

   328,952   322,288 

Long-term debt

   290,016   301,530 

Deferred taxes

   51,668   46,411 
   


 


Total liabilities

   670,636   670,229 

STOCKHOLDERS’ EQUITY

         

Common stock

   1,381   1,378 

Additional paid-in capital

   132,853   124,212 

Accumulated other comprehensive income

   9,677   8,519 

Retained earnings

   989,431   901,829 

Notes receivable from ESOP

   (20,866)  (20,866)
   


 


Total stockholders’ equity

   1,112,476   1,015,072 
   


 


Total liabilities and stockholders’ equity

  $1,783,112  $1,685,301 
   


 


   January 28,
2006
  April 30,
2005
 
   (Unaudited)    

ASSETS

   

Current assets:

   

Cash and cash equivalents

  $185,986  $232,549 

Short-term investments

   2,005   13,382 

Receivables, net

   312,954   317,168 

Inventory

   242,573   206,405 

Prepaid expenses and other current assets

   30,453   30,533 
         

Total current assets

   773,971   800,037 

Property and equipment, net

   125,019   97,178 

Long-term receivables, net

   46,790   33,573 

Goodwill

   657,606   632,549 

Identifiable intangibles, net

   109,733   113,530 

Distribution agreement

   100,000   —   

Other

   7,651   8,434 
         

Total assets

  $1,820,770  $1,685,301 
         

LIABILITIES AND STOCKHOLDERS’ EQUITY

   

Current liabilities:

   

Accounts payable

  $145,236  $160,954 

Accrued payroll expense

   48,143   43,132 

Other accrued expenses

   83,995   77,317 

Income taxes payable

   7,983   20,858 

Current maturities of long-term debt

   20,027   20,027 
         

Total current liabilities

   305,384   322,288 

Long-term debt

   285,022   301,530 

Deferred taxes

   54,162   46,411 
         

Total liabilities

   644,568   670,229 

STOCKHOLDERS’ EQUITY

   

Common stock

   1,386   1,378 

Additional paid-in capital

   140,726   124,212 

Accumulated other comprehensive income

   11,521   8,519 

Retained earnings

   1,043,435   901,829 

Notes receivable from ESOP

   (20,866)  (20,866)
         

Total stockholders’ equity

   1,176,202   1,015,072 
         

Total liabilities and stockholders’ equity

  $1,820,770  $1,685,301 
         

See accompanying notes.

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share amounts)

(Unaudited)

 

   Three Months Ended

  Six Months Ended

 
   October 29,
2005


  October 30,
2004


  

October 29,

2005


  October 30,
2004


 

Net sales

  $641,697  $578,237  $1,237,544  $1,156,180 

Cost of sales

   422,483   373,610   811,086   747,584 
   


 


 


 


Gross profit

   219,214   204,627   426,458   408,596 

Operating expenses

   146,388   134,568   284,118   270,935 
   


 


 


 


Operating income

   72,826   70,059   142,340   137,661 

Other income and (expense):

                 

Finance income, net

   1,479   1,180   3,575   2,501 

Interest expense

   (3,109)  (3,791)  (6,186)  (7,549)

Gain on currency exchange

   243   447   212   488 
   


 


 


 


Income before taxes

   71,439   67,895   139,941   133,101 

Income taxes

   26,719   25,391   52,339   49,782 
   


 


 


 


Net income

  $44,720  $42,504  $87,602  $83,319 
   


 


 


 


Earnings per share:

                 

Basic

  $0.33  $0.31  $0.64  $0.61 
   


 


 


 


Diluted

  $0.32  $0.31  $0.63  $0.60 
   


 


 


 


Weighted average common shares:

                 

Basic

   137,554   136,737   137,427   136,630 
   


 


 


 


Diluted

   139,249   138,795   139,183   138,702 
   


 


 


 


   Three Months Ended  Nine Months Ended 
   

January 28,

2006

  January 29,
2005
  January 28,
2006
  January 29,
2005
 

Net sales

  $682,402  $638,005  $1,919,946  $1,794,185 

Cost of sales

   441,433   410,677   1,252,519   1,158,261 
                 

Gross profit

   240,969   227,328   667,427   635,924 

Operating expenses

   152,423   145,549   436,541   416,484 
                 

Operating income

   88,546   81,779   230,886   219,440 

Other income and (expense):

     

Finance income, net

   1,106   1,533   4,681   4,034 

Interest expense

   (3,470)  (3,303)  (9,656)  (10,852)

Gain on currency exchange

   85   89   297   577 
                 

Income before taxes

   86,267   80,098   226,208   213,199 

Income taxes

   32,263   29,961   84,602   79,743 
                 

Net income

  $54,004  $50,137  $141,606  $133,456 
                 

Earnings per share:

     

Basic

  $0.39  $0.37  $1.03  $0.98 
                 

Diluted

  $0.39  $0.36  $1.02  $0.96 
                 

Weighted average common shares:

     

Basic

   137,804   136,924   137,552   136,728 
                 

Diluted

   139,275   138,960   139,214   138,788 
                 

See accompanying notes.

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands)

(Unaudited)

 

   Six Months Ended

 
   October 29,
2005


  October 30,
2004


 

Operating activities:

         

Net income

  $87,602  $83,319 

Adjustments to reconcile net income to net cash provided by operating activities:

         

Depreciation

   7,672   7,418 

Amortization of intangibles

   3,256   5,816 

Stock-based compensation

   390   —   

Bad debt expense

   1,171   773 

Change in assets and liabilities, net of acquired

   (32,187)  28,085 
   


 


Net cash provided by operating activities

   67,904   125,411 

Investing activities:

         

Additions to property and equipment, net

   (27,166)  (13,386)

Acquisitions, net

   (32,728)  (72,762)

Distribution agreement

   (100,000)  —   

Sale (purchase) of short-term investments, net

   9,369   (12,373)
   


 


Net cash used in investing activities

   (150,525)  (98,521)

Financing activities:

         

Payments and retirement of long-term debt and obligations under capital leases

   (10,014)  (60,420)

Common stock issued, net

   8,644   9,036 
   


 


Net cash used in financing activities

   (1,370)  (51,384)

Effect of exchange rate changes on cash

   (511)  3,140 
   


 


Net decrease in cash and cash equivalents

   (84,502)  (21,354)

Cash and cash equivalents at beginning of period

   232,549   287,160 
   


 


Cash and cash equivalents at end of period

  $148,047  $265,806 
   


 


   Nine Months Ended 
   January 28,
2006
  January 29,
2005
 

Operating activities:

   

Net income

  $141,606  $133,456 

Adjustments to reconcile net income to net cash provided by operating activities:

   

Depreciation

   12,028   10,960 

Amortization of intangibles

   4,939   9,279 

Stock-based compensation

   570   —   

Bad debt expense

   1,925   1,128 

Change in assets and liabilities, net of acquired

   (45,235)  36,454 
         

Net cash provided by operating activities

   115,833   191,277 

Investing activities:

   

Additions to property and equipment, net

   (36,721)  (22,590)

Acquisitions, net

   (39,228)  (72,855)

Distribution agreement

   (100,000)  —   

Sale (purchase) of short-term investments, net

   11,377   (4,207)
         

Net cash used in investing activities

   (164,572)  (99,652)

Financing activities:

   

Payments and retirement of long-term debt and obligations under capital leases

   (15,021)  (65,586)

Common stock issued, net

   16,522   13,179 
         

Net cash provided by (used in) financing activities

   1,501   (52,407)

Effect of exchange rate changes on cash

   675   2,965 
         

Net (decrease) increase in cash and cash equivalents

   (46,563)  42,183 

Cash and cash equivalents at beginning of period

   232,549   287,160 
         

Cash and cash equivalents at end of period

  $185,986  $329,343 
         

See accompanying notes.

PATTERSON COMPANIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars and share amounts in thousands except per share data)

(Unaudited)

October 29, 2005January 28, 2006

NOTE 1 GENERAL

Basis of Presentation

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of October 29, 2005January 28, 2006 and the results of operations and the cash flows for the periods ended OctoberJanuary 28, 2006 and January 29, 2005 and October 30, 2004.2005. Such adjustments are of a normal recurring nature. The results of operations for the periods ended OctoberJanuary 28, 2006 and January 29, 2005, and October 30, 2004, are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the financial statements included in the 2005 Annual Report on Form 10-K filed on July 14, 2005.

The condensed consolidated financial statements of Patterson Companies, Inc. include the assets and liabilities of PDC Funding Company, LLC (“PDC Funding”), a wholly owned subsidiary and a separate legal entity under Minnesota law. PDC Funding is a fully consolidated special purpose entity of the Company established to sell customer installment sale contracts to outside financial institutions in the normal course of business. The assets of PDC Funding would be available first and foremost to satisfy the claims of its creditors. There are no known creditors of PDC Funding.

Fiscal Year End

The fiscal year end of the Company is the last Saturday in April. The secondthird quarter of fiscal 2006 and 2005 represent the 13 weeks ended OctoberJanuary 28, 2006 and January 29, 2005, and October 30, 2004, respectively. Because of the Company’s long established practice of using a 52/53-week fiscal year convention, the first sixnine months of fiscal 2006 include 2639 weeks of operations while the first sixnine months of fiscal 2005 include 2740 weeks.

Reclassifications

Certain amounts previously reported have been reclassified to conform to the current presentation.

Comprehensive Income

Total comprehensive income was $46,800$55,848 and $88,760$144,608 for the three and sixnine months ended October 29, 2005,January 28, 2006, respectively, and $46,805$49,887 and $89,585$139,472 for the three and sixnine months ended October 30, 2004,January 29, 2005, respectively. Other than net income, comprehensive income includes foreign currency translation effects and changes in unrealized gains and losses on cash flow hedging instruments.

Distribution Agreement

In the first quarter of fiscal 2006, the Company extended its exclusive North American distribution agreement with Sirona Dental Systems GmbH (“Sirona”) for Sirona’s CEREC 3D dental restorative system. The Company paid a $100 million distribution fee to extend the agreement for a 10-year period that begins in October 2007. The distribution fee is reflected as a non-current asset in the condensed consolidated balance sheet. The amortization of this fee will occur over the 10-year period and will reflect the pattern in which the economic benefits of the fee are realized.

Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:share (shares in thousands):

 

   Three Months Ended

  Six Months Ended

   October 29,
2005


  October 30,
2004


  October 29,
2005


  October 30,
2004


Denominator:

            

Denominator for basic earnings per share - weighted-average shares

  137,544  136,737  137,427  136,630

Effect of dilutive securities:

            

Stock option plans

  1,392  1,723  1,480  1,776

Employee Stock Purchase Plan

  37  44  37  44

Capital Accumulation Plan

  217  232  180  193

Convertible debentures

  59  59  59  59
   
  
  
  

Dilutive potential common shares

  1,705  2,058  1,756  2,072
   
  
  
  

Denominator for diluted earnings per share - adjusted weighted-average shares and assumed conversions

  139,249  138,795  139,183  138,702
   
  
  
  

   Three Months Ended  Nine Months Ended
   January 28,
2006
  January 29,
2005
  January 28,
2006
  January 29,
2005

Denominator:

        

Denominator for basic earnings per share - weighted-average shares

  137,804  136,924  137,552  136,728

Effect of dilutive securities:

        

Stock option plans

  1,159  1,640  1,374  1,730

Employee Stock Purchase Plan

  45  39  40  42

Capital Accumulation Plan

  252  298  204  229

Convertible debentures

  15  59  44  59
            

Dilutive potential common shares

  1,471  2,036  1,662  2,060
            

Denominator for diluted earnings per share - adjusted weighted-average shares and assumed conversions

  139,275  138,960  139,214  138,788
            

Options to purchase 59479 and 30180 shares of common stock during the three and sixnine months ended October 29, 2005January 28, 2006 are excluded from the calculation of diluted EPS because the effect would have been anti-dilutive. There are 13 and 5943 shares of restricted stock awards outstanding, including performance unit awards, which are excluded from the calculation of diluted EPS during the three and sixnine months ended October 29, 2005,January 28, 2006, respectively, because the effect would have been anti-dilutive. There were no anti-dilutive securities outstanding during the three and sixnine months ended October 30, 2004,January 29, 2005, respectively.

NOTE 2 GOODWILL AND OTHER INTANGIBLE ASSETS

The goodwill balances and related activity by business segment as of April 30, 2005 and October 29, 2005 isJanuary 28, 2006 are as follows:

 

  

Balance at

April 30, 2005


  

Acquisition

Activity


  

Translation

And Other

Activity


  

Balance at

October 29, 2005


  

Balance at

April 30, 2005

  

Acquisition

Activity

  

Translation

And Other

Activity

  

Balance at

January 28, 2006

Dental Supply

  $77,437  $13,077  $110  $90,624  $77,437  $13,266  $230  $90,933

Rehabilitation Supply

   482,535   —     —     482,535   482,535   —     —     482,535

Veterinary Supply

   72,577   3,364   84   76,025   72,577   11,477   84   84,138
  

  

  

  

            

Total

  $632,549  $16,441  $194  $649,184  $632,549  $24,743  $314  $657,606
  

  

  

  

            

The increase in the goodwill balance during the six-monthnine-month period ended October 29, 2005 primarilyJanuary 28, 2006 reflects the preliminary purchase price allocation of the Accu-Bite, Inc. acquisitionand Intra Corp acquisitions (see Note 5) and contingent earn-out payments related to acquisitions made in prior years. The preliminary purchase price allocation isallocations are subject to adjustment for changes in the preliminary assumptions pending additional information, including final asset valuations.

Balances of acquired intangible assets excluding goodwill are as follows:

 

  October 29,
2005


 April 30,
2005


   January 28,
2006
 April 30,
2005
 

Copyrights, trade names and trademarks - unamortized

  $76,402  $76,402   $76,402  $76,402 

Customer lists and other amortizable intangible assets

   60,921   59,827    60,969   59,827 

Less: Accumulated amortization

   (25,966)  (22,699)   (27,638)  (22,699)
  


 


       

Net amortizable

   34,955   37,128    33,331   37,128 
  


 


       

Total identifiable intangible assets, net

  $111,357  $113,530   $109,733  $113,530 
  


 


       

NOTE 3 STOCK-BASED COMPENSATION

The Company has adopted the disclosure requirements of SFAS No. 148,Accounting for Stock-Based Compensation-Transition and Disclosure, an amendment of FASB Statement 123. The Company has chosen to continue with its current practice of applying the recognition and measurement principles of APB No. 25,Accounting for Stock Issued to Employees. This method defines the Company’s cost as the excess of the stock’s market value at the time of the grant over the amount that the employee is required to pay. No compensation expense has been recorded related to stock options as all options granted had an exercise price equal to or greater than the market value of the underlying common stock on the measurement date.

During the six-monthsnine-months ended October 29, 2005,January 28, 2006, the Company issued approximately 90,000 restricted stock awards (“RSAs”) and 13,000 performance unit awards (“PUAs”) to employees. The RSAs vest over a seven or nine-year period and are subject to forfeiture provisions. Certain RSAs are subject to accelerated vesting provisions beginning three years after the grant date, based on certain operating goals. The PUAs are earned at the end of a three-year period if certain operating goals are met, and are settled in an equivalent number of common shares or in cash as determined by the compensation committee of the Board of Directors. If these goals are not met, the PUAs are cancelled. The fair values of the RSAs and PUAs are expensed over the expected vesting periods. The Company recognized approximately $0.2 million and $0.4$0.6 million of expense, net of related tax benefit, related to RSAs and PUAs during the three and six-monthnine-month periods ended October 29, 2005,January 28, 2006, respectively. There were no such awards issued or outstanding in any periods prior to fiscal 2006.

The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of SFAS No. 123, “Accounting for Stock Based Compensation” to stock-based employee compensation:

 

   Three Months Ended

  Six Months Ended

 
   October 29,
2005


  October 30,
2004


  October 29,
2005


  October 30,
2004


 

Net income, as reported

  $44,720  $42,504  $87,602  $83,319 

Add: Stock-based employee compensation expense included in reported net income, net of related tax effects

   190   —     390   —   

Deduct: Stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects

   (1,075)  (534)  (2,155)  (1,080)
   


 


 


 


Pro forma net earnings

  $43,835  $41,970  $85,837  $82,239 
   


 


 


 


Earnings per share—basic:

                 

As reported

  $0.33  $0.31  $0.64  $0.61 

Pro forma

  $0.32  $0.31  $0.63  $0.61 

Earnings per share—diluted:

                 

As reported

  $0.32  $0.31  $0.63  $0.60 

Pro forma

  $0.31  $0.30  $0.62  $0.60 

   Three Months Ended  Nine Months Ended 
   January 28,
2006
  January 29,
2005
  January 28,
2006
  January 29,
2005
 

Net income, as reported

  $ 54,004  $ 50,137  $ 141,606  $ 133,456 

Add: Stock-based employee compensation expense included in reported net income, net of related tax effects

   180   —     570   —   

Deduct: Stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects

   (1,090)  (636)  (3,245)  (1,716)
                 

Pro forma net earnings

  $53,094  $49,501  $138,931  $131,740 
                 

Earnings per share—basic:

     

As reported

  $0.39  $0.37  $1.03  $0.98 

Pro forma

  $0.39  $0.36  $1.01  $0.96 

Earnings per share—diluted:

     

As reported

  $0.39  $0.36  $1.02  $0.96 

Pro forma

  $0.38  $0.36  $1.00  $0.95 

On December 16, 2004, the FASB issued Statement No. 123 (revised 2004),Share-Based Payment (SFAS 123R). SFAS 123R is a revision of Statement No. 123,Accounting for Stock-Based Compensation, and supersedes Accounting Principles Board (APB) Opinion No. 25,Accounting for Stock Issued to Employees, and its related implementation guidance. SFAS 123R eliminates the ability to account for share-based compensation transactions using the intrinsic value method under APB Opinion No. 25 and generally requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments (including employee stock options) based on the grant-date fair value of the award.

The options for transition methods as prescribed by SFAS 123R include either the modified prospective or the modified retrospective methods. The modified prospective method requires that compensation expense be recorded for all unvested stock options as the requisite service is rendered beginning with the first quarter of adoption, while the modified retrospective method would record compensation expense for stock options beginning with the first period restated. Under the modified retrospective method, prior periods may be restated either as of the beginning of the year of adoption or for all periods presented. The restated amounts would be consistent with those that have been reported in pro forma disclosures under SFAS No. 148 and are included in the notes to the Company’s financial statements. Those results are not necessarily indicative of future results.

SFAS 123R will be effective for the Company beginning in its first quarter of fiscal 2007, unless adopted earlier.2007. The Company is currently evaluating SFAS 123R to determine the date of adoption, which fair-value-based model and transitional provision will be followed upon adoption, and the impact it may have on the Company’s consolidated financial statements.

NOTE 4 DERIVATIVE FINANCIAL INSTRUMENTS

In fiscal 2004, the Company entered into a swap agreement in the notional amount of $100 million that exchanged a floating interest rate payment obligation for a fixed rate payment obligation. The swap has beenwas designated as a cash flow hedging instrument. The contract iswas recorded at fair value on the balance sheet and all changes in fair value arewere deferred in accumulated other comprehensive income because the agreement has been determined to be perfectly effective. Upon recognitionThis interest rate swap agreement terminated in the statement of income, such gains or losses are recorded as an adjustment to interest expense.November, 2005. The fair value of the interest rate swap agreement as of October 29, 2005 and April 30, 2005 was estimated at $0.5 million and $0.9 million, respectively. The fair value of the interest rate swap agreement is the estimated amount the Company would pay or receive to terminate the agreement at the reporting date, taking into account current interest rates, market expectations for future interest rates and the Company’s current creditworthiness. This interest rate swap agreement terminated in November, 2005.

million.

In the first quarter of fiscal 2006, the Company entered into certain offsetting and identical interest rate cap agreements. These cap agreements are not designated for hedge accounting treatment and were entered into to fulfill certain covenants of a sale agreement between a commercial paper conduit managed by JPMorgan Chase Bank, N.A. and PDC Funding. The cap agreements provide a credit enhancement feature for the installment contracts sold by PDC Funding to the commercial paper conduit, and replace a minimum interest rate margin previously required under the sale agreement.

PDC Funding purchased two interest rate caps from banks with combined amortizing notional amounts of $400 million. At the same time, Patterson Companies, Inc. sold two identical interest rate caps to the same banks. The fair value of the two purchased interest rate caps at October 29, 2005January 28, 2006 was approximately $0.4$0.3 million. This amount was completely offset by the fair value of the two sold interest rate caps of ($0.4)0.3) million. Accordingly, the impact to consolidated earnings of the Company is zero. The Company was not a party to any such interest rate cap agreements prior to fiscal 2006.

Also in fiscal 2006, the Company entered into an interest rate swap agreement with a bank under which the Company pays a fixed rate and receives a floating rate based on an amortizing notional amount. This agreement does not qualify for hedge accounting treatment and, accordingly, the Company records the fair value of the agreement as an asset or liability and the change in any period as income or expense of the period in which the change occurs. As of January 28, 2006, the notional amount of this agreement was approximately $45 million and there was a nominal estimated fair value.

The Company has limited involvement with derivative financial instruments and does not use financial instruments or derivatives for any trading or other speculative purposes.

NOTE 5 ACQUISITIONS

In December 2005, the Company acquired Intra Corp (“IntraVet”), a developer of veterinary practice management software that is marketed under the IntraVet brand name. In September 2005, the Company acquired Accu-Bite, Inc., (“Accu-Bite”) a Michigan-based dental distributor, in andistributor. The acquisition of both IntraVet and Accu-Bite were all-cash transaction.transactions. During fiscal 2005, the Company completed

several acquisitions, including CAESY Education Systems and Medco Supply Company, Inc. in May 2004 and Milburn Distributions, Inc. in October 2004. Additionally, the Company acquired a small dental equipment dealer in September 2004. The operating results of these acquisitions are included in the Company’s condensed consolidated statements of income from the date of acquisition. Pro forma results of operations have not been presented for these acquisitions since the effects of the acquisitions were not material to the Company either individually or in the aggregate.

NOTE 6 SEGMENT REPORTING

Patterson Companies, Inc. is comprised of three reportable segments: dental, veterinary, and rehabilitation supply. The Company’s reportable business segments are strategic business units that offer similar products and services to different customer bases. The dental supply segment provides a virtually complete range of consumable dental products, clinical and laboratory equipment and value-added services to dentists, dental laboratories, institutions and other dental healthcare providers throughout North America. The veterinary supply segment provides consumable supplies, equipment, diagnostic products, biologicals (vaccines) and pharmaceuticals to companion-pet veterinary clinics in various regions of the United States, including the Eastern, Midwest, Mid-Atlantic, Southeastern, and Northwest regions. The rehabilitation supply segment provides a comprehensive range of distributed and self-manufactured rehabilitation medical supplies and non-wheelchair assistive products to acute care hospitals, long-term care facilities, rehabilitation clinics, dealers and schools.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies set forth in Note 1 to the consolidated financial statements included in the Company’s 2005 Annual Report on Form 10-K filed July 14, 2005. The Company evaluates segment performance based on operating income. The corporate office general and administrative expenses are included in the dental supply segment and consist of home office support costs in areas such as informational technology, marketing, purchasing, finance, human resources and facilities.

The following table presents information about the Company’s reportable segments:

 

  Three Months Ended

  Six Months Ended

  Three Months Ended  Nine Months Ended
  October 29,
2005


  October 30,
2004


  

October 29,

2005


  October 30,
2004


  January 28,
2006
  January 29,
2005
  January 28,
2006
  January 29,
2005

Net sales

                    

Dental supply

  $480,080  $438,918  $912,136  $864,535  $531,884  $499,796  $1,444,020  $1,364,331

Rehabilitative supply

   78,800   75,205   157,350   152,450   69,755   67,508   227,105   219,958

Veterinary supply

   82,817   64,114   168,058   139,195   80,763   70,701   248,821   209,896
  

  

  

  

            

Consolidated net sales

  $641,697  $578,237  $1,237,544  $1,156,180  $682,402  $638,005  $1,919,946  $1,794,185
  

  

  

  

            

Operating income

                    

Dental supply

  $54,560  $54,229  $104,477  $103,939  $73,589  $67,998  $178,066  $171,937

Rehabilitative supply

   14,352   12,897   30,078   27,313   11,311   10,618   41,389   37,931

Veterinary supply

   3,914   2,933   7,785   6,409   3,646   3,163   11,431   9,572
  

  

  

  

            

Consolidated operating income

  $72,826  $70,059  $142,340  $137,661  $88,546  $81,779  $230,886  $219,440
  

  

  

  

            

The following table presents sales information by product category for the Company:

 

   Three Months Ended

  Six Months Ended

   October 29,
2005


  October 30,
2004


  October 29,
2005


  October 30,
2004


Net sales

                

Consumable and printed products

  $418,010  $367,140  $818,350  $757,003

Equipment and software

   176,724   167,675   326,787   312,659

Other

   46,963   43,422   92,407   86,518
   

  

  

  

Total

  $641,697  $578,237  $1,237,544  $1,156,180
   

  

  

  

   Three Months Ended  Nine Months Ended
   January 28,
2006
  January 29,
2005
  January 28,
2006
  January 29,
2005

Net sales

        

Consumable and printed products

  $406,447  $365,408  $1,224,797  $1,122,411

Equipment and software

   227,771   229,349   554,558   542,008

Other

   48,184   43,248   140,591   129,766
                

Total

  $682,402  $638,005  $1,919,946  $1,794,185
                

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

This Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) should be read in conjunction with the MD&A included in our 2005 Annual Report on Form 10-K filed July 14, 2005, for important background information regarding, among other things, an overview of the markets in which we operate and our business strategies. Notes 4, 5 and 6 to the accompanying condensed consolidated financial statements are incorporated by reference into this discussion.

RESULTS OF OPERATIONS

The following table sets forth, for the periods indicated, the percentage of net sales represented by certain operational data.

 

   Three Months Ended

  Six Months Ended

 
   October 29,
2005


  October 30,
2004


  October 29,
2005


  October 30,
2004


 

Net sales

  100.0% 100.0% 100.0% 100.0%

Cost of sales

  65.8% 64.6% 65.5% 64.7%
   

 

 

 

Gross margin

  34.2% 35.4% 34.5% 35.3%

Operating expenses

  22.8% 23.3% 23.0% 23.4%
   

 

 

 

Operating income

  11.4% 12.1% 11.5% 11.9%

Other (expense) income, net

  (0.2)% (0.4)% (0.2)% (0.4)%
   

 

 

 

Income before income taxes

  11.2% 11.7% 11.3% 11.5%

Net income

  7.0% 7.4% 7.1% 7.2%

   Three Months Ended  Nine Months Ended 
    January 28,
2006
  January 29,
2005
  January 28,
2006
  January 29,
2005
 

Net sales

  100.0% 100.0% 100.0% 100.0%

Cost of sales

  64.7% 64.4% 65.2% 64.6%
             

Gross margin

  35.3% 35.6% 34.8% 35.4%

Operating expenses

  22.3% 22.8% 22.7% 23.2%
             

Operating income

  13.0% 12.8% 12.1% 12.2%

Other (expense) income, net

  (0.3)% (0.3)% (0.3)% (0.3)%
             

Income before income taxes

  12.7% 12.5% 11.8% 11.9%

Net income

  7.9% 7.9% 7.4% 7.4%

QUARTER ENDED OCTOBER 29, 2005JANUARY 28, 2006 COMPARED TO QUARTER ENDED OCTOBER 30, 2004.JANUARY 29, 2005.

Net Sales. Net sales for the three months ended October 29, 2005January 28, 2006 (“Current Quarter”) totaled $641.7$682.4 million, an 11.0%a 7.0% increase from $578.2$638.0 million reported for the three months

ended October 30, 2004January 29, 2005 (“Prior Quarter”). The Current Quarter included one less selling day than the Prior Quarter, which negatively impacted the growth rate by an estimated 1-2 percentage points.

The Company acquired Accu-Bite Dental, Inc. (“Accu-Bite”) in September 2005 and Milburn Distributions, Inc.Intra Corp (“Milburn”IntraVet”) in October 2004.December 2005. Excluding the impact of these two acquisitions, sales rose approximately 7.1%4.3%. The impact of foreign exchange rate changes on net sales for the Current Quarter was approximately 0.5% of total net sales.

Dental segment sales were $480.1$531.9 million in the Current Quarter, which was an increase of 9.4%6.4% from $438.9$499.8 million in the Prior Quarter. Sales of consumable dental supplies and printed office products increased 12%12.1% in the Current Quarter. Excluding the impact of the Accu-Bite acquisition, sales of these products were up 7.4%6.0%. Dental equipment and software sales rose 5.5%, driven by double-digitdecreased 1.1%. Strong sales growth of digital radiography equipment and related software, including the CEREC®line of CAESY patient education software, largely offset flat sales of basic equipment and modestly lower sales of CEREC® 3D dental restorative systems and digital radiography equipment. Basic equipment sales growth and the Accu-Bite acquisition each had a minimal contribution to total equipment sales growth in the Current Quarter.systems. Finally, sales of other services and products, consisting primarily of parts, technical service labor, software support, and insurance e-claims increased 10.9%13.1% in the Current Quarter.

Veterinary sales increased 29.2%14.2% from $64.1$70.7 million in the Prior Quarter to $82.8$80.8 million in the Current Quarter. ExcludingThe IntraVet acquisition had a nominal impact on sales growth. The veterinary segment’s sales of equipment and software grew to $5.7 million in the impactCurrent Quarter, an increase of 65.1% from the Milburn acquisition, sales growth was approximately 14%.Prior Quarter. The rehabilitation unit reported sales of $78.8$69.8 million, reflecting approximately 5%3.3% sales growth in the Current Quarter.

This sales growth reflected a negative impact of foreign currency translation on sales of approximately 1.4%.

Gross Margins. Consolidated gross margin decreased from 35.4%35.6% to 34.2%35.3% in the Current Quarter as compared to the Prior Quarter. This decline resulted from several different factors.

Within the dental unit, gross margin was affected bylargely due to the acquisition of Accu-Bite, which haswhose gross margins are currently lower margins than the Company’s historic dental unit’s traditional margin. Additionally,levels. Accu-Bite was acquired in September 2005 and continues to be integrated into the Company’s existing dental operations.

In addition, the consolidated gross margin was negatively affectedimpacted by strong sales growth of the veterinary segment because this segment has the lowest gross margin of the Company’s three businesses. While still producing a shift duringlower gross margin than the other two businesses, the veterinary unit improved its own gross margin by 80 basis points in the Current Quarter, in the interest rate curve used to mark-to-market the Company’s residual interest inwhich was a finance contract portfolio. This shift was nearly double what the Company has experienced in other quarters and resulted in a reductionresult of the residual interest adjustment on a comparable basis.

The Veterinary supply business experienced a decline in its gross marginincreased sales of 80 basis points due mostly to the impact of the Milburn equine business, whose margins are below Webster Veterinary’s historic standards. The Current Quarter included the anniversary of this transactionequipment and as a result, future quarters are not expected to experience similar impacts on gross margins on a comparable basis.

software.

Patterson Medical’s gross margin declined approximately 60150 basis points quarter-over-quarter, due to product mix as well as increases in freight costs.

Operating Expenses. In the Current Quarter, operating expenses as a percent of sales were 22.8%22.3%. This ratio represented a reduction of 50 basis points as compared to 23.3%22.8% in the Prior Quarter, reflecting the impact ofstrengthened operating leverage and a lower level of intangible asset amortization primarily in the rehabilitation supply unit, and increased operating leverage at the veterinary supply unit. The dental unit’s operating expense ratio, which was adversely affected by the Accu-Bite acquisition, was unchanged quarter-over-quarter.

Operating Income. Operating income was $72.8$88.5 million, or 11.4%13.0% of net sales in the Current Quarter. This percentage was lowerapproximately 20 basis points higher than the 12.1%12.8% reported in the Prior Quarter and reflected the Company’s lower gross margin,improved operating expense ratio, partially offset by an improved operating expense ratio.a decline in consolidated gross margin.

Other Expense, Net.Net other expense was $1.4$2.3 million for the Current Quarter compared to $2.2$1.7 million in the Prior Quarter. The reductionInterest expense was due primarily to less interest expense resulting$3.5 million in the Current Quarter, up slightly from $3.3 million in the Company reducing its outstandingPrior Quarter despite a lower debt balance over the past year. The weighted average effective interest rate on debt was approximately 3.9% in the Current Quarter. An interest rate swap agreement, under which the Company had effectively been paying a fixed rate on $100 million of its variable rate debt, terminated in November 2005. Due to the swap termination, an increase in theThe weighted average effective interest rate ofon debt was approximately 0.5% is anticipated4.5% in the thirdCurrent Quarter, up from 3.3% in the Prior Quarter. A rate similar to the Current Quarter is expected in the Company’s fourth quarter of fiscal 2006.

Income Taxes.The effective income tax rate for the Current Quarter was 37.4%, which was consistent with the Prior Quarter.

Earnings Per Share.Earnings increased 5.2%7.7% to $44.7$54.0 million, resulting in diluted earnings per share of $0.32$0.39 versus $0.31$0.36 in the Prior Quarter.

SIXNINE MONTHS ENDED OCTOBER 29, 2005JANUARY 28, 2006 COMPARED TO SIXNINE MONTHS ENDED OCTOBER 30, 2004.JANUARY 29, 2005.

Net Sales. Net sales for the six months ended October 29, 2005Nine Months Ended January 28, 2006 (“Current Period”) totaled $1,237.5$1,919.9 million, a 7.0% increase from $1,156.2$1,794.2 million reported for the six months ended October 30, 2004Nine Months Ended January 29, 2005 (“Prior Period”). Sales for the Current Period included the contributions from the Accu-Bite and Milburn acquisitions. The Prior Period included the impact of an extra or twenty-seventhfortieth week resulting from the Company’s long-standing convention of using a fifty-two, fifty-three week fiscal year ending on the final Saturday of April. Fiscal year 2005 was a fifty-three week year, while fiscal year 2006 will be a fifty-two week year.

It is difficult to precisely quantify the impact of an extra week on six-monthnine-month operating results since certain aspects of the Company’s business, such as equipment sales and contract services, are not as directly affected by the additional billing days.

Dental segment sales of $912.1$1,444.0 million in the Current Period represented an increase of 5.5%5.8% from $864.5$1,364.3 million the Prior Period. Sales of consumables and printed office products (“Consumables”) were $523.5$797.9 million, or 5.4%7.7% higher than $496.6$740.7 million in the Prior Period. The Company estimates the impact of the extraadditional week in the Prior Period and the acquisition of Accu-Bite each had an impact on Consumables sales to be approximately $18.9 million. The Accu-Bite acquisition impact inthe comparability of the Current Period on Consumables was approximately $10.4 million. Adjusting forPeriod. Excluding these two factors,items from the respective period, consumables sales growth was approximately 7.4%7.0% in the Current Period.

Veterinary segment sales rose to $168.1$248.8 million, up 20.7%18.5% from $139.2$209.9 million in the Prior Period. Excluding the estimated impact of the extra week on the Prior Period and the Milburn acquisition,impact of acquisitions, sales growth in the veterinary segment was approximately 8.5%10.1%.

The rehabilitation business unit reported Current Period sales of $157.4$227.1 million, which was 3.2% higher than Prior Period sales of $152.5$220.0 million. Excluding the estimated impact of the extra week on Prior Period sales, growth was 6.7%5.7%.

Gross Margins. Current Period consolidated gross margin was 34.5%34.8% as compared to the Prior Period margin of 35.3%35.4%. The period-over-period decline resulted from several different factors.

Gross margins at the dental unit were down 6040 basis points in the Current Period, due to a decline in the second quarter, resulting partly fromprimarily to the acquisition of Accu-Bite, which has lower margins than the dental unit’s traditional margin. Additionally, dental unit gross margin was negatively affected by a shift during the Current Quarter in the interest rate curve used to mark-to-market the Company’s residual interest in a finance contract portfolio as discussed above.

The Veterinary supply business experienced a decline in its gross margin of 7020 basis points due to the impact of a full nine-months of the Milburn equine business, whose margins are below Webster Veterinary’s historic standards.

Patterson Medical’s gross margin declined approximately 7090 basis points period-over-period, due to product mix and increases in freight costs and strong Current Period sales from its Medco division, which carries lower gross margin than the other divisions of the Medical unit.

costs.

Operating Expenses. Operating expenses as a percent of sales were 23.0%22.7% in the Current Period, which was a reduction from 23.4%23.2% in the Prior Period. The lower operating expense ratio was due largely to two factors.

First, the Current Period included a lower level of intangible asset amortization at the rehabilitation unit. Secondly, the dental and veterinary unit has gainedboth achieved modest improvement due to operating leverage, on higher sales. In addition, in the Prior Period, the veterinary unit was integrating the less efficient operations of the April 2004 ProVet acquisition that resulted in extra operating expense.

The dental segment’s Current Periodlowering their operating expense ratio was consistent with the ratio in the Prior Period.

10 and 20 basis points, respectively.

Operating Income. Operating income was $142.3$230.9 million, or 11.5%12.1% of net sales in the Current Period. This percentage was lowerslightly less than the 11.9%12.2% reported in Prior Period and reflected the Company’s lower gross margin, partially offset by an improved operating expense ratio, both as discussed above.

Other Expense, Net.Net other expense was reduceddecreased from $4.6$6.2 million in the Prior Period to $2.4$4.7 million in the Current Period. This reduction resulted fromThe primary reason for the combination of two factors. First,decrease was lower interest expense, which was $6.2 million in the Current Period, down from $7.5$10.9 million in the Prior Period and $9.7 million in the Current Period. The Company carried less debt on its balance sheet during the Current Period due to the Company’s principal payments on outstanding debt over the past year. Additionally,Higher effective interest rates partially offset the Company’s interest income rose to $3.6 million inimpact of the Current Period as compared to $2.5 million in the prior period, due largely to higher interest rates.lower debt balances.

Income Taxes.The effective income tax rate for the Current Period was 37.4%, which was consistent with the Prior Period.

Earnings Per Share.Earnings increased 5.1%6.1% to $ 87.6$141.6 million, resulting in diluted earnings per share of $0.63$1.02 versus $0.60$0.96 in the Prior Period.

LIQUIDITY AND CAPITAL RESOURCES

For the six months ended October 29, 2005 (“Current Period”),Period, the Company generated $67.9$115.8 million of cash from operations on earnings of $87.6$141.6 million, compared to $125.4$191.3 million on earnings of $83.3$133.5 million in the six months ended October 30, 2004 (“Prior Period”).Period. The operating cash flow from operations forin the six months ended October 30, 2004Prior Period was favorably impacted by a difference in the sequencing of ourthe Company’s routine cash disbursement cycle and ourthe Company’s fiscal year calendar. This difference caused about one additional week of trade payables to be outstanding at the end of the Prior Period. Cash

Investing cash flows in the Current Period also reflectedreflect the $100 million distribution fee that was paid for a 10-year extension of the Company’s exclusive North American distribution agreement of Sirona’s CEREC equipment.

Capital expenditures were $27.2$36.7 million in the Current Period. Significant capital expenditures in fiscal 2006 included a new printed office products facility, a new distribution facility for Patterson Medical’s U.K. operation, and new shared distribution center projects in Kent, Washington and Lancaster, Pennsylvania. The new printed office products facility and the Washington distribution center both became operational in the first quarter of fiscal 2006. The U.K. andfacility is expected to be operational in the fourth quarter of fiscal 2006. The Pennsylvania distribution facility projects wereis expected to be operational in progress asthe first quarter of October 29, 2005.

fiscal 2007.

The Company expects funds generated by operations, existing cash balances and availability under existing debt facilities will be sufficient to meet the Company’s working capital needs and finance anticipated expansion plans and strategic initiatives over the next fiscal year.

CRITICAL ACCOUNTING POLICIES

There has been no material change in the Company’s Critical Accounting Policies, as disclosed in its 2005 Annual Report on Form 10-K filed July 14, 2005.

FACTORS THAT MAY AFFECT FUTURE OPERATING RESULTS

Certain information of a non-historical nature contains forward-looking statements. Words such as “believes,” “expects,” “plans,” “estimates,” “intends” and variations of such words are intended to identify such forward-looking statements. These statements are not guaranties of future performance and are subject to certain risks, uncertainties or assumptions that are difficult to predict; therefore, the Company cautions shareholders and prospective investors

that the following important factors, among others, could cause the Company’s actual operating results to differ materially from those expressed in any forward-looking statements. The statements under this caption are intended to serve as cautionary statements within the meaning of the Private Securities Litigation Reform Act of 1995. The following information is not intended to limit in any way the characterization of other statements or information under other captions as cautionary statements for such purpose. The order in which such factors appear below should not be construed to indicate their relative importance or priority. The Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

The Company’s ability to meet increased competition from national, regional and local full-service distributors and mail-order distributors of dental, veterinary and rehabilitation and assistive living products, while maintaining current or improved profit margins.

 

The ability of the Company to retain its base of customers and to increase its market share.

 

The ability of the Company to maintain satisfactory relationships with qualified and motivated sales personnel.

 

The continued ability of the Company to maintain satisfactory relationships with key vendors and the ability of the Company to create relationships with additional manufacturers of quality, innovative products.

 

Changes in the economics of dentistry affecting dental practice growth and the demand for dental products, including the ability and willingness of dentists to invest in high-technology diagnostic and therapeutic products.

 

Reduced growth in expenditures for dental services by private dental insurance plans.

 

The accuracy of the Company’s assumptions concerning future per capita expenditures for dental services, including assumptions as to population growth and the demand for preventive dental services such as periodontic, endodontic and orthodontic procedures.

 

The rate of growth in demand for infection control products currently used for prevention of the spread of communicable diseases such as AIDS, hepatitis and herpes.

 

Changes in the economics of the veterinary supply market, including reduced growth in per capita expenditures for veterinary services and reduced growth in the number of households owning pets.

 

The effects of healthcare related legislation and regulation, which may affect expenditures or reimbursements for rehabilitation and assistive products.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes since April 30, 2005 in the Company’s market risk. The weighted-average interest rate on the Company’s debt for the Current Period was approximately 3.9%4.5%. An interestA similar rate swap under which the Company has effectively been paying a fixed rate on $100 million of its variable rate debt terminated in November 2005. Due to the swap termination, an increase in the effective interest rate of approximately 0.5% is anticipated in the thirdfourth quarter of fiscal 2006. As discussed in Note 4 to the condensed consolidated financial statements, the Company entered into certain offsetting interest rate cap agreements during the first quarter ofand an interest rate swap agreement in fiscal 2006 that, on2006. On a consolidated basis, these agreements do not materially impact the Company’s market risk. For further information on market risk, refer to Item 7A in the Company’s 2005 Annual Report on Form 10-K filed July 14, 2005.

ITEM 4. CONTROLS AND PROCEDURES

Under the supervision and with the participation of the Company’s management, including the Company’s President and Chief Executive Officer (“CEO”) and its Chief Financial Officer (“CFO”), management evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of October 29, 2005.January 28, 2006. Based upon their evaluation of these disclosure controls and procedures, the CEO and CFO concluded that the disclosure controls and procedures were effective as of October 29, 2005.

January 28, 2006.

There were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f) under the Exchange Act) that occurred during the quarter ended October 29, 2005January 28, 2006 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Five purported class action lawsuits werehave been filed during the second quarter of fiscal 2006 in the United States District Court for the District of Minnesota, naming the Company and certain officers and directors and alleging certain violations of the federal securities laws. On August 31, 2005, the Court entered an order consolidating the cases into a single action captionedIn re Patterson Companies, Inc. Securities Litigationdocketed as File No. 05cv1757 DSD/NMJ. On September 16, 2005, a derivative lawsuit was filed in the United States District Court for the District of Minnesota captionedVance Cadd, Derivatively On Behalf of Patterson Companies, Inc. vs. James W. Wiltz, et al., docketed as File No. 05-cv-02155 RHK/AJB. This lawsuit names certain officers and directors of the Company as defendants and alleges breach of fiduciary duty, abuse of control, gross mismanagement, waste of corporate assets and unjust enrichment. On October 11, 2005, a class action lawsuit was filed in the United States District Court for the District of Minnesota captionedTamara Dolliver, On Behalf of Herself and All Others Similarly Situated vs. Patterson Companies, Inc., et al docketed as File No. 05-cv-02383 JNE/SRN. This class action lawsuit was brought on behalf of the participants in the Company’s Employee Stock Ownership Plan against the Company and certain officers and directors, and alleges violations of the federal Employee Retirement Income Security Act. TheCaddandDolliver cases are predicated on essentially the same factual allegations alleged in, and are related cases to, the class action lawsuits consolidated asIn Re Patterson Companies, Inc. Securities Litigation. Because of the status of the proceedings in these lawsuits, as well as the contingencies and uncertainties associated with litigation, it is not possible to predict the exposure that the Company will have, if any, in connection with the claims. The Company believes that the allegations made against it in these lawsuits are without merit and it intends to vigorously defend the claims.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

 (c)In September 2004, the Company’s Board of Directors approved a stock repurchase program under which the Company may repurchase up to six million shares of common stock in open market transactions. The Company did not repurchase any shares under the program during the quarter ended October 29, 2005January 28, 2006 and has not made any repurchases since the program’s approval in September 2004. As of October 29, 2005,January 28, 2006, the Company had authority to repurchase six million shares under that program. The repurchase authorization expires on September 30, 2009.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At the Company’s Annual Meeting of Shareholders held on September 12, 2005, the Company’s shareholders approved the following matters:

1.ELECTION OF DIRECTORS

   Voted for

  Withheld

To serve for a three-year term expiring in 2008:

      

Ronald E. Ezerski

  120,247,353  8,897,086

Andre B. Lacy

  120,700,273  8,444,166

There were no abstentions or broker non-votes. The other directors of the Company whose terms in office continued after the 2005 Annual Meeting of Shareholders are as follows: terms expiring at the 2006 Annual Meeting—Ellen A. Rudnick, Harold C. Slavkin and James W. Wiltz; and term expiring at the 2007 Annual Meeting—Peter L. Frechette.

2.RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL 2006. The vote was 125,274,180 for, 3,791,559 against, and 78,700 abstentions. There were no broker non-votes.

ITEM 6. EXHIBITS

The exhibits listed in the accompanying exhibit index are filed as part of this Quarterly Report on Form 10-Q.

All other items under Part II have been omitted because they are inapplicable or the answers are negative, or were previously reported in the 2005 Annual Report on Form 10-K filed July 14, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  

PATTERSON COMPANIES, INC.

(Registrant)

Dated: March 9, 2006

 PATTERSON COMPANIES, INC.
 (Registrant)
Dated: December 8, 2005
 By: 

/s/ R. Stephen Armstrong


  R. Stephen Armstrong
  Executive Vice President, Chief Financial Officer and Treasurer
  (Principal Financial Officer and Principal Accounting Officer)

EXHIBIT INDEX

 

Exhibit
Number


 

Exhibit Description


31.1 Certification of the Chief Executive Officer pursuant to Rule 13a-4(a)13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 Certification of the Chief Financial Officer pursuant to Rule 13a-4(a)13a-14(a) or 15d-14(a), under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2 Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

2221